全国性 BNT162b2 mRNA COVID-19 疫苗接种计划的初步影响。
The initial impact of a national BNT162b2 mRNA COVID-19 vaccine rollout.
机构信息
Communicable Disease Center, Hamad Medical Corporation, Doha, Qatar; Division of Infectious Diseases, Department of Medicine, Hamad Medical Corporation, Doha, Qatar.
Communicable Disease Center, Hamad Medical Corporation, Doha, Qatar.
出版信息
Int J Infect Dis. 2021 Jul;108:116-118. doi: 10.1016/j.ijid.2021.05.021. Epub 2021 May 13.
OBJECTIVE
This study examined the initial impact of a national BNT162b2 vaccine rollout on SARS-CoV-2 infections in Qatar.
METHODS
All individuals who had completed ≥14 days of follow-up by 16 March 2021 after receiving the BNT162b2 vaccine were included. This study calculated incidence rates (IR) and their 95% confidence intervals (CI) during days 1-7, 8-14, 15-21, 22-28, and >28 days post-vaccination. Poisson regression was used to calculate incidence rate ratios (IRR) relative to the first 7-day post-vaccination period.
RESULTS
A total of 199,219 individuals with 6,521,124 person-days of follow-up were included. SARS-CoV-2 infection was confirmed in 1877 (0.9%), of which 489 (26.1%) were asymptomatic and 123 (6.6%) required oxygen support. The median time from first vaccination to SARS-CoV-2 confirmation was 11.9 days (IQR 7.7-18.2). Compared with the first 7-day post-vaccination period, SARS-CoV-2 infections were lower by 65.8-84.7% during 15-21, 22-28, and >28 days (P < 0.001 for each). For severe COVID-19, the incidence rates were 75.7-93.3% lower during the corresponding time periods (P < 0.001 for each).
CONCLUSION
The results were consistent with an early protective effect of BNT162b2 vaccine against all degrees of SARS-CoV-2 severity.
目的
本研究考察了 BNT162b2 疫苗在卡塔尔全国范围内推出对 SARS-CoV-2 感染的初始影响。
方法
所有在 2021 年 3 月 16 日之后完成 ≥14 天随访的个体均被纳入本研究。本研究计算了疫苗接种后第 1-7、8-14、15-21、22-28 天和 >28 天的发病率（IR）及其 95%置信区间（CI）。采用泊松回归计算了相对于第 1 次接种后 7 天的发病率比值（IRR）。
结果
共纳入 199219 名个体，随访 6521124 人天。共确诊 1877 例 SARS-CoV-2 感染（0.9%），其中 489 例（26.1%）为无症状，123 例（6.6%）需要吸氧支持。从首次接种到 SARS-CoV-2 确诊的中位数时间为 11.9 天（IQR 7.7-18.2）。与第 1 次接种后 7 天相比，15-21、22-28 和 >28 天的 SARS-CoV-2 感染率降低了 65.8-84.7%（P<0.001）。对于严重 COVID-19，相应时间段内的发病率降低了 75.7-93.3%（P<0.001）。
结论
结果表明 BNT162b2 疫苗对 SARS-CoV-2 严重程度的各个级别均有早期保护作用。
Zotero 插件